We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Exhaled-Breath Test Shows Promise for Detection of Lung Cancer

By LabMedica International staff writers
Posted on 19 Jul 2024

Researchers are advancing the development of an exhaled-breath test to detect lung diseases, including lung cancer. More...

Two pivotal studies published in the Journal of Extracellular Vesicles detail their success in isolating and analyzing lung biomarkers from human breath and utilizing animal models to further explore and possibly identify crucial markers for the early and non-invasive detection of metastatic lung tumors. While substantial efforts are needed to identify a spectrum of biomarkers and validate their clinical relevance for human patients, these publications provide a scientific framework for continued research.

The research by scientists at Hackensack Meridian Health (Edison, NJ, USA) focuses on capturing and characterizing extracellular vesicles (EVs), nanoparticles released by cells into fluids like blood and serum. Cancer cells release these particles abundantly, making them prime targets for early disease detection. The researchers have initiated biomarker discovery projects for several cancers, including lung, prostate, cervical, and bladder cancers, using liquid biopsies. They have developed a technology called EV-CATCHER that selectively isolates these nanoparticles from biofluids and employs next-generation sequencing to examine small-RNAs within the nanoparticles for non-invasive detection of lesions and tumors that could be developing within the body. The team is now applying the EV-CATCHER technology to isolate EVs from human exhaled breath, which carries biomarkers of lung disease, potentially transforming the diagnosis and monitoring of lung conditions without invasive lung sampling.

In their most recent study, they analyzed airway samples from 69 individuals, demonstrating that microRNA profiles in exhaled EVs matched those from deeper lung samples obtained through more invasive methods like bronchoalveolar lavages. In another pivotal study aimed at detecting lung cancer, they analyzed microRNA content in exhaled EVs collected from breath condensates of 18 individuals—12 healthy and six with stage-IV lung cancer. Their findings revealed distinct microRNA expression profiles in exhaled EVs that could differentiate between individuals with and without lung cancer. An earlier study with mouse models, published in March in the journal Extracellular Vesicles and Circulating Nucleic Acids, demonstrated the ability to detect microRNAs from human-derived tumor cells in exhaled breath within 1-2 weeks of injecting human cancer cells, using EV-CATCHER to capture tumor EVs from exhaled breath. Although further refinement of biomarker selection is necessary, the research indicates promising potential for diagnosing lung diseases, notably lung cancer, using this innovative approach.

“We envision that expanding our approach to study human primary and other secondary lung cancers, in adequately-powered animal studies, has the potential to identify relevant exhaled human EV biomarkers,” they wrote. “Furthermore, since EV-CATCHER can easily be customized to target surface markers of specific EV subpopulations, we foresee that using it to separate lung tumor cell-derived exhaled EVs from immune and innate cell-derived EVs may help further improve the selection of exhaled tumor EVs for the fine-tuned detection of different types of lung cancer.”

Related Links:
Hackensack Meridian Health


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Portable Electronic Pipette
Mini 96
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: The collaboration aims to improve access to Hb variant testing with the Gazelle POC diagnostic platform (Photo courtesy of Hemex Health)

Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders

Millions of people worldwide living with sickle cell disease and other hemoglobin disorders experience delayed diagnosis and limited access to effective care, particularly in regions where testing is scarce.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.